Compounds > olmesartan
Page last updated: 2024-09-04

olmesartan and diltiazem

olmesartan has been researched along with diltiazem in 3 studies

Compound Research Comparison

Studies
(olmesartan)		Trials
(olmesartan)		Recent Studies (post-2010)
(olmesartan)		Studies
(diltiazem)		Trials
(diltiazem)		Recent Studies (post-2010) (diltiazem)
8411855546,4021,073578

Protein Interaction Comparison

ProteinTaxonomyolmesartan (IC50)diltiazem (IC50)
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)0.45
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)0.605
Cytochrome P450 3A4Homo sapiens (human)1.8366
Voltage-dependent L-type calcium channel subunit alpha-1CRattus norvegicus (Norway rat)0.896
Voltage-dependent L-type calcium channel subunit alpha-1DRattus norvegicus (Norway rat)0.896
Sodium channel protein type 1 subunit alphaHomo sapiens (human)9
Sodium channel protein type 4 subunit alphaHomo sapiens (human)9
Sodium channel protein type 7 subunit alphaHomo sapiens (human)9
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)0.605
Voltage-dependent L-type calcium channel subunit alpha-1SRattus norvegicus (Norway rat)0.896
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)0.605
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)0.605
Sodium channel protein type 5 subunit alphaHomo sapiens (human)9
Sodium channel protein type 9 subunit alphaHomo sapiens (human)9
Sodium channel protein type 2 subunit alphaHomo sapiens (human)9
Sodium channel protein type 3 subunit alphaHomo sapiens (human)9
Sodium channel protein type 11 subunit alphaHomo sapiens (human)9
Sodium channel protein type 8 subunit alphaHomo sapiens (human)9
Sodium channel protein type 10 subunit alphaHomo sapiens (human)9

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ1

Other Studies

3 other study(ies) available for olmesartan and diltiazem

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity

2013